LipovaxinS4-EAH

Phase of Development

Phase 1

Vaccine Platform

Protein / Adjuvant

Candidate Overview

Lipovaxin Tuberculosis Vaccine – Subunit candidate vaccine comprising fusion antigen ESAT6-Ag85C (Fusion RV-3875 and Rv0129c) formulated with liposome platform and equipped with PHAD adjuvant (TLR 4 agonist)

Sponsor / Lead Developer: PT Bio Farma (Persero)

Development partner(s): Lipotek

Primary Indication: Prevention of TB disease

Target Population(s): Adolescents and Adults

Target Route of Administration: Intramuscular

Clinical Trials

ACTIVE TRIALS
Registry ListingNCT07647107
Clinical Trial PhasePhase 1
Clinical Trial SponsorPT Bio Farma
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults

Source: Vaccine developer

Date Updated/Reviewed: 12-Oct-2026